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pidemiologic studies show an inverse correlation between garlic consumption and progression of 
cardiovascular disease. Cardiovascular disease is associated with multiple factors such as raised serum 
total cholesterol, raised LDL and an increase in LDL oxidation, increased platelet aggregation, hypertension, 
and smoking. Numerous in vitro studies have confirmed the ability of garlic to reduce these parameters. 
Thus, garlic has been shown to inhibit enzymes involved in lipid synthesis, decrease platelet aggregation, 
prevent lipid peroxidation of oxidized erythrocytes and LDL, increase antioxidant status, and inhibit 
angiotensin-converting enzyme. These findings have also been addressed in clinical trials. The studies point to 
the fact that garlic reduces cholesterol, inhibits platelet aggregation, reduces blood pressure, and increases 
antioxidant status. Since 1993, 44% of clinical trials have indicated a reduction in total cholesterol, and the most 
profound effect has been observed in garlic's ability to reduce the ability of platelets to aggregate. Mixed results 
have been obtained in the area of blood pressure and oxidative-stress reduction. The findings are limited 
because very few trials have addressed these issues. The negative results obtained in some clinical trials may 
also have resulted from usage of different garlic preparations, unknown active constituents and their 
bioavailability, inadequate randomization, selection of inappropriate subjects, and short duration of trials. This 
review analyzes in vitro and in vivo studies published since 1993 and concludes that although garlic appears to 
hold promise in reducing parameters associated with cardiovascular disease, more in-depth and appropriate 
studies are required. 
Keywords: Allium sativum, hypercholesterolemia, antioxidants, cardioprotective, HMG-CoA reductase.
1. INTRODUCTION 
Cardiovascular disease is a complex and 
multifactorial disease and is characterized by 
multiple factors. Epidemiologic studies have 
identified these as elevated serum lipids (cholesterol 
and triglycerides), increased plasma fibrinogen and 
coagulation factors, increased platelet activation, 
alterations in glucose metabolism, and smoking 
(Wood., et al 2001). The oxidative modification of 
LDL by reactive oxygen species (ROS) 4 is also now 
considered as an important mechanism in the 
development of atherosclerosis, as is the 
pathogenesis of hypertension (Dhawan., et al  
2004). There is also considerable evidence 
supporting the involvement of platelets in the 
development of atherosclerosis. Increased platelet 
activity has been found in smokers as well as in 
patients suffering from vascular injury, 
hyperlipidemia, and hypertension. Increased HDL 
levels are negatively correlated with cardiovascular 
disease. Normalization of abnormal lipids and 
lipoproteins, hypertension, inhibition of platelet 
aggregation, and an increase in antioxidant status 
are believed to improve cardiovascular disease.  
2. GARLIC 
Garlic (Allium sativum) is believed to have originated 
in Central Asia and belongs to the Alliacae family. It 
is used universally as a flavoring agent, traditional 
medicine, and a functional food to enhance physical 
and mental health. The beneficial effects of garlic 
consumption in treating a wide variety of human 
diseases and disorders have been known for 
centuries; thus, garlic has acquired a special position 
in the folklore of many cultures as a formidable 
prophylactic and therapeutic medicinal agent. It is 
even cited in the Egyptian Codex Ebers, a 
3,500-yr-old document, as useful in the treatment of 
heart disorders, tumors, worms, bites, and other 
ailments (Rahman K., 2000). Garlic is also reported 
to inhibit the pathogenesis of cardiovascular disease 
and to prevent cancer and other chronic diseases 
associated with aging (Rahman K., 2000). Over the 
last one-quarter century the role of garlic in treating 
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cardiovascular disease has received much attention. 
The majority of garlic (65%) is water, and the bulk 
of the dry weight is composed of fructose-containing 
carbohydrates, followed by sulfur compounds, 
protein, fiber, and free amino acids (Lawson., 1996). 
It also contains high levels of saponins, phosphorus, 
potassium, sulfur, zinc, moderate levels of selenium 
and Vitamins A and C, and low levels of calcium, 
magnesium, sodium, iron, manganese, and 
B-complex vitamins; garlic also has a high phenolic 
content (Vinson., 2001). A majority of the 
compounds present in garlic are water-soluble (97%) 
with small amounts of oil-soluble compounds also 
present (0.15–0.7%). Over the years different garlic 
preparations have been investigated for their 
prevention and treatment of cardiovascular disease 
both in vitro and in vivo (clinical trials). The 
common preparations that have been investigated 
are raw garlic, garlic powder tablets, oil of 
steam-distilled garlic, oil of oil-macerated garlic, 
ether-extracted oil of garlic, and aged garlic extract 
(AGE). All these preparations differ in their 
composition (Banerjee., 2003), which makes 
comparing studies difficult 
3. IN-VITRO STUDIES  
Numerous in vitro studies have confirmed the ability 
of garlic to reduce parameters associated with 
cardiovascular disease. A brief description of some of 
these studies is given below. 
Cholesterol and lipid-lowering effects 
Several studies have indicated that garlic and its 
constituents inhibit key enzymes involved in 
cholesterol and fatty acid synthesis in cultured rat 
hepatocytes and human HepG2 cells (Yeh YY., 2001). 
Direct measurements of enzyme activity have 
indicated that garlic and various constituents inhibit 
human squalene monooxygenase and HMG-CoA 
reductase enzymes involved in cholesterol 
biosynthesis (Gupta N., 2001). This inhibition of 
HMG-CoA reductase by garlic has also been 
confirmed in a recent study (Augusti KT., 2005). It 
has also been shown that the more water-soluble 
compounds like S-allylcysteine (SAC) present in aged 
garlic extract are less cytotoxic and more efficient in 
inhibiting cholesterol biosynthesis than the 
lipid-soluble sulfur compounds such as diallyl sulfide 
(DAS) (Yeh YY., 2001). 
Antithrombotic and anti–platelet aggregatory effects 
Platelet aggregation and subsequent thrombus 
formation are significantly reduced by garlic and its 
constituents. Chloroform/acetone extracts of fresh 
garlic have been shown to inhibit cyclooxygenase 
activity directly in cell-free assays, with the acetone 
extract being more effective (Sendl., 1992). In this 
study, the chloroform extract of garlic was a more 
effective inhibitor of ADP- and platelet-activating 
factor (PAF)-induced platelet aggregation. The 
mechanism of inhibition of platelet aggregation by 
garlic's constituents has also been addressed, and it is 
thought to work via the inhibition of calcium 
mobilization (Qi R., 2000). Ajone, another garlic 
derivative, has also been shown to inhibit platelet 
aggregation in vitro (Teranishi K., 2001). A recent 
study has also found another garlic component, 
sodium 2-propenyl thiosulfate, to modulate 
cyclooxygenase activity in canine platelets, thus 
preventing their aggregation (Chang., et al 2005). 
Blood coagulation, fibrinolysis and circulatory effects 
Fibrinolysis is also enhanced by garlic, resulting in 
dissolution of clots and thrombi. In vitro studies have 
demonstrated that aged garlic extract improves 
circulation and blood properties by preventing lipid 
peroxidation and hemolysis in oxidized erythrocytes 
(Moriguchi., et al 2001). A recent study has 
confirmed that garlic improves the fluidity of 
erythrocytes isolated from hypecholesterolemic rats 
(Kempaiah., et al 2005). In contrast, garlic oil 
extracts and the allyl sulfides were unable to protect 
isolated erythrocytes from t-butyl 
hydroperoxide-induced hemolysis (Wu CC., et al 
2001). 
Blood pressure and vascular tone effects 
A garlic extract has been shown to modulate the 
production and function of both 
endothelium-derived relaxing factor (NO) and 
constricting factors (endothelin-1) in isolated rat 
pulmonary arteries (Kim-Park., et al 2000). Garlic 
juice has also been shown to have some beneficial 
effect on heart rate; however, at higher dosages it 
exerts undesirable effects (Yadav., et al 2001). 
γ-Glutamylcysteines are compounds 0found in garlic, 
and these may lower blood pressure, as indicated by 
their ability to inhibit angiotensin-converting 
enzyme in vitro (Sendl., et al 1992). 
Effects on endogenous antioxidant defenses 
Numerous studies have investigated the antioxidant 
properties of garlic in various in vitro systems; some 
of these are outlined below. Garlic has been shown to 
inhibit the in vitro oxidation of isolated human LDL 
by scavenging superoxide (ROS) and inhibiting the 
formation of lipid peroxides (Dillon., et al 2002). In 
vitro studies have shown that AGE prevents the 
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depletion of intracellular glutathione (GSH) when 
endothelial cells are incubated with oxidized LDL 
(Ide and BHS., 2001). AGE also increases GSH levels 
in vascular endothelial cells by modulation of the 
GSH redox cycle and increases glutathione disulfide 
(GSSG) reductase activity while increasing SOD 
activity (Geng and BHS., 1997). 
 
In vitro (preclinical) studies have confirmed that 
garlic has the ability to reduce parameters 
associated with cardiovascular disease. However, 
such studies need to be translated into a clinical 
setting, the results of which are discussed below. 
4. IN-VIVO STUDIES  
A limited number of clinical trials have been 
conducted with different garlic preparations. In this 
review an attempt has been made to critically review 
human trials, which have been conducted since 1993. 
Only those trials that were conducted for a minimum 
period of 2 week and that addressed the following 
parameters have been included: (a) 
cholesterol-lowering effects, (b) inhibition of platelet 
aggregation, (c) lowering of blood pressure, and (d) 
other cardioprotective properties. 
Cholesterol-lowering effects 
Since 1993, 25 clinical trials have been published 
that have investigated the hypolipidemic effects of 
garlic (Zhang XH., et al 2001; Ganji V., 1998; 
Tanamai., et al 2004, Peleg., 2003). Fourteen of the 
studies showed that garlic had no effect on lowering 
cholesterol, but 11 studies showed a reduction in 
serum cholesterol. It is interesting to note that of the 
14 studies showing no effects, 5 were in 
normolipidemic subjects, 8 were in moderately 
hypercholesterolemic subjects, and 1 study was in 
teenagers with familial hypercholesterolemia .A 
further breakdown of these 14 studies shows that 9 
used garlic powder, 4 used AGE, and 1 used 
steam-distilled garlic oil. The 11 studies that showed 
a positive effect on cholesterol reduction were 
performed in hypercholesterolemic subjects; 5 
studies used AGE, and the rest used garlic powder  
It is apparent that garlic is effective in 
hypercholesterolemic subjects, and it may well be 
that a reduction in cholesterol will be seen only 
above a certain threshold. Another factor that may 
need to be taken into account is the gender of the 
subjects. Zhang e., et al (2001) reported that gender 
might affect the action of garlic on plasma 
cholesterol and glucose levels of normal subjects. A 
systematic review of the effectiveness of garlic as an 
antihyperlipidemic agent was published in 2003 by 
Alder., et al. (2003) .They included 10 studies and 
found that in 6 studies garlic was effective in 
reducing serum cholesterol levels. The average drop 
in total cholesterol was 9.9%, LDL 11.4%, and 
triglycerides 9.9%. Earlier metaanalysis has also 
confirmed that garlic is superior to a placebo in 
reducing total cholesterol levels (Stevinson., et al 
2000,Ackermann., et al 2001). However, the size of 
the effect is modest, and the robustness of the effect 
is open to question. 
Inhibition of platelet aggregation 
Since 1993, 7 clinical trials have been performed, 
and all have shown that garlic consumption leads to 
the inhibition of platelet aggregation (Rahman K., 
2003; Maulik SK., 2002; Steiner M., 2001). Of these 7 
studies, 4 were performed in healthy subjects, and 3 
in subjects with coronary artery disease/mild 
hypercholesterolemia. Two studies involved garlic 
powder, 1 oil extract, 1 ethyl acetate extract, and 3 
studies involved aged garlic extract. Garlic has a 
positive response in the inhibition of platelet 
aggregation in both healthy subjects and subjects 
with cardiovascular disease. 
Lowering of blood pressure 
Since 1993, 9 studies have been published on the 
effects of garlic on blood pressure (Maulik SK., 2002; 
Turner., et al 2004; Dhawan., et al 2004). Two 
studies used AGE, 3 used garlic powder, and 1 used 
garlic in the diet, and all these studies showed a 
reduction in blood pressure. Three studies utilized 
Kwai garlic and did not report any change in the 
blood pressure In support of this, a metaanalysis 
published in 2001 (Ackermann., et al 2001) 
concluded that garlic has insignificant effects on 
blood pressure. 
Other cardio protective properties 
Oxidative stress can lead to the pathogenesis of 
cardiovascular disease, and some clinical trials 
involving garlic have addressed this. Seven studies 
since 1993 have been identified One was performed 
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in patients with essential hypertension, and garlic 
pears were used. A reduction in blood pressure and a 
decrease in oxidative stress were reported (Dhawan., 
et al 2004). Four studies (2 in normal subjects, 2 in 
hypercholetrolemic subjects) used AGE and reported 
a decrease in oxidative stress (Durak., et al 2004; 
Munday., et al 1999; Dillion., et al 2002). In contrast, 
2 studies utilizing garlic tablets (1 in normal subjects 
and 1 in hypercholeterolemic subjects) did not show 
a reduction in oxidative-stress parameters (Banerjee 
SK and Maulik SK., 2002; Durak., et al 2004). One of 
the studies, which showed a reduction in oxidative 
stress after garlic ingestion, was conducted in our 
laboratory in healthy smoking and nonsmoking men 
and women. In this study F2-isoprostanes were 
measured because their quantification in plasma 
and urine is a sensitive and specific indicator of 
oxidative stress in vivo. Dietary supplementation 
with AGE for 14 d reduced plasma and urine 
concentrations of F2-isoprostanes by 29% and 37%, 
respectively, in nonsmokers and by 35% and 48%, 
respectively, in smokers. Fourteen days after 
cessation of dietary supplementation, plasma and 
urine concentrations of F2-isoprostanes in both 
groups returned to values not different from those 
before ingestion (It was also observed in this study 
that the plasma antioxidant capacity of nonsmokers 
was approximately twice that of smokers. 
Interestingly, the plasma antioxidant capacity of 
smokers significantly increased by 53% following 
supplementation with AGE for 14 d (However, after 
the 2-wk washout period (day 28), the plasma 
antioxidant capacity of smokers decreased by 49% 
and was now similar to that before AGE ingestion; 
the plasma antioxidant capacity of nonsmokers 
remained unaffected during this same period  
The subjects in this study were normolipidemic, and 
no other changes including those of serum lipids 
were seen in this study. This underscores the point 
that multiple questions must be addressed in clinical 
trials incorporating any new and specific markers. 
The conclusion from this study was that dietary 
supplementation with AGE reduces oxidative stress 
in humans and thus may prevent or delay chronic 
diseases such as cardiovascular disease. 
Other direct cardioprotective effects of garlic in 
humans have also been reported, such as a decrease 
in unstable angina (Byrne., et al 1999), an increase 
in the elastic property of blood vessels (Li G., et al 
2000) and a decrease in peripheral arterial occlusive 
disease (Breithaupt-Grogler K., et al 1997). More 
recently, garlic has been shown to increase 
peripheral blood flow in healthy subjects 
(Kiesewetter H., et al 1993) while inhibiting the 
progression of coronary calcification in patients 
receiving statin therapy (Anim-Nyame N., et al 
2004). However, the number of trials conducted 
within this area is limited. 
Conflicting message and variable results: why? 
In-vitro studies strongly suggest that garlic has the 
ability to reduce parameters associated with 
cardiovascular disease. This has prompted a number 
of clinical studies, some of which give conflicting 
messages. The reasons for these are outlined below. 
(a) A limited number of trials have been performed; 
some have been of short durations including 
inadequate randomization and blinding procedures. 
(b) Different garlic preparations have different 
properties. Raw garlic's composition is variable, and 
some toxicity has been reported. Allicin has some 
antioxidant properties, but it has not been detected 
in serum or urine after ingestion of raw garlic, and it 
has also been reported to oxidize LDL. Garlic powder 
must be prepared at a suitable temperature and is 
associated with some toxicity. No major studies on 
the efficacy of garlic oils have been reported 
(Banerjee SK., et al 2003). The composition of AGE 
is such that it has increased sulfur compounds with 
the loss of allicin. (c) There is also substantial 
variability in the contents of garlic preparations, 
with inadequate definitions of the biologically active 
and available constituents and their dissolution 
properties. This makes it difficult to ascertain the 
consistency of garlic's effect in these trials. (d) In 
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some trials there are a lack of intention-to-treat 
analyses and incomplete reporting of data. (e) Some 
trials have not addressed the right questions 
(normolipidemic versus hyperlipidemic subjects?). 
The appropriate cardiovascular endpoints need to be 
defined. Would we expect a reduction in serum 
cholesterol of normolipidemic subjects? Do we really 
want this? 
5. DISCUSSION 
Dietary factors play a key role in the development of 
some human diseases, including cardiovascular 
disease. It has also been suggested that the benefits 
of fruit and vegetable consumption appear to be 
primarily related to cardiovascular disease and not 
cancer. These foods contain phytochemicals that 
have anticancer and anti-inflammatory properties, 
which confer many health benefits. One source of 
such phytochemicals is garlic, whose role in the 
prevention and treatment of cardiovascular diseases 
(and cancer) is best known throughout the world. 
It is important that standardized preparations of 
garlic are used in clinical trials and the bioavailability 
of the active constituents is established. It is also 
important to ask the right questions: are we looking 
at the prevention or treatment of cardiovascular 
disease by garlic? One also needs to conduct 
well-designed randomized trials that are of sufficient 
duration so morbidity and mortality outcomes, as 
well as lipid and thrombotic outcomes, can be 
addressed. It is also perhaps more important to 
investigate whether garlic taken as dietary 
supplement can either delay or prevent 
cardiovascular disease in a healthy population. It 
may well be that if garlic is taken before the onset of 
cardiovascular disease, the outcome will be different. 
This is supported by some epidemiologic evidence. 
Finally, it is important that new biomarkers and 
methodologies in cardiovascular disease are 
incorporated into the clinical trials, and if a positive 
effect is observed, the mechanism of action on the 
disease parameters must be established. 
Cardiovascular disease is complex and multifactorial, 
and garlic has multiple properties that may reduce 
cardiovascular disease; hence, multiple questions 
must be addressed in clinical trials. 
In summary, evidence from clinical trials points that 
garlic have a major role to play in either preventing 
or delaying cardiovascular disease. However, more 
research is still required to convince health workers, 
consumers, and regulatory bodies. 
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